Don't count out Cipher Pharma, Research Capital says - Cantech Letter
Cipher Pharmaceuticals' stock dropped due to Moberg Pharma's disappointing interim clinical update on MOB-015, a nail fungus treatment. Despite this, Research Capital's Andre Uddin maintains a 'Buy' rating on Cipher, citing MOB-015's previous efficacy and its approval in 13 European countries, predicting potential Health Canada approval and stock recovery.
Reference News
Don't count out Cipher Pharma, Research Capital says - Cantech Letter
Cipher Pharmaceuticals' stock dropped due to Moberg Pharma's disappointing interim clinical update on MOB-015, a nail fungus treatment. Despite this, Research Capital's Andre Uddin maintains a 'Buy' rating on Cipher, citing MOB-015's previous efficacy and its approval in 13 European countries, predicting potential Health Canada approval and stock recovery.